Monograph Capital Partners
Venture capitalActively deployingLondon · Seed–Series B · 23 people tracked
Also known as MONOGRAPH CAPITAL ADVISORS (UK), LLP · MONOGRAPH CAPITAL ADVISORS, L.P.
Investment thesis
Monograph Capital invests in innovative life sciences companies with the goal of turning promising science into life-changing treatments for patients worldwide. The firm operates as a transatlantic team focused on sourcing leading scientific innovation and supporting company development across geographic boundaries. It combines differentiated deal sourcing, long-standing relationships with pharmaceutical companies, deep medical expertise, and seasoned operating experience to build strong companies and create value for both company partners and investors, ultimately aiming to improve patient health outcomes over time.
Source: firm website, verified Aug 25, 2026.
Team · 23 people
from the firm's website & curated & public directories
Founder mafia
3 people who came through Monograph Capital Partners went on to found or lead other companies.
What they invest in
from 14 of 23 portfolio companiesBiotech ×12Healthtech ×10Medical Devices ×7Deep Tech ×3Digital Health ×3AI & Machine Learning ×2SaaS ×2Enterprise Software ×1
HQs:United States×7United Kingdom×3Germany×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×42 founders×33 founders×1
Investments · 23 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12023 · 25 dated
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))Mai-Britt Zocca(CEO)
Co-investorsSofinnova PartnersForbion
Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs.
BiotechHealthtechCambridge, GB
John McCafferty(Co-founder and CTO)inAneesh Karatt-Vellatt(Co-founder and CSO)in
Co-investorsLifeArc VenturesGeneral CatalystSolasta Ventures
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)PETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)CHRISTOPHER SILBER(Executive Officer)
Board seatFreddie Dear· per SEC Form D
Co-investorsCanaan PartnersF-Prime CapitalMission BiocapitalOUP (Osage University Partners)Osage University Partners
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
BiotechAustin, US
Jason Ehrlich(Executive Officer, Director)
BoardFred Cohen(Director)Alaa Halawa(Director)Cariad Chester(Director)Paul Berns(Director)
Board seatTravis Murdoch· per SEC Form D
Co-investorsARCH Venture PartnersMC Healthcare VenturesTCG Crossover
A gene-to-GMP contract development and manufacturing organization for advanced modalities and gene therapies.
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
Co-investorsCathay HealthDigitalis Ventures
A clinical-stage biotechnology company developing adjunctive therapies for depressive illnesses and bipolar depression.
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersPfizer Venture InvestmentsSamsara BioCapitalNewpath Partners
AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
BiotechDeep TechDigital HealthHealthtech
Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)Do Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)Lisa Deschamps(Chief Executive Officer)Graeme Fielder(Chief Operating Officer)Alex Bloom(Chief Development Officer)
Co-investorsAdvent Life SciencesDementia DiscoveryF-Prime CapitalLifeArc VenturesNew Enterprise Associates (NEA)
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more
Biotech company developing antibodies to treat autoimmune and inflammatory diseases.
Co-investorsArkin CapitalJeito Capital
A precision immunology company co-incubated with Arch Venture Partners leveraging human genetics for autoimmune disorder treatments (exited May 2024).
Co-investorsARCH Venture Partners
A UK-based preclinical biotechnology company developing antibody drugs against ion channels and GPCRs using proprietary KnotBody technology.
Co-investorsGeneral CatalystLifeArc Ventures
A therapeutics company developing checkpoint agonist antibodies for autoimmune disease treatment based on Oxford University research (exited August 2022).
Co-investorsAdvent Life SciencesMedicxiOxford Science EnterprisesSamsara BioCapital
ODAIA offers Marketing Intelligence, a platform for pharmaceutical marketing and sales teams that ties channel-level actions to prescription (Rx) outcomes and coordinates healthcare provider (HCP) engagement across digital and field channels.
AI & Machine LearningDigital HealthHealthtechMarketing TechSaaSSales Tech
Philip Poulidis(Founder)in
Co-investorsGraphite VenturesPanache VenturesStand Up VenturesThreshold VenturesToronto Innovation Acceleration PartnersWittington Ventures+5 more
Co-investorsAndreessen HorowitzTCG Crossover
Ouro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions.
BiotechHealthtechSouth San Francisco, US
Jaideep(Founding Chief Executive Officer)Neely Mozaffarian(Chief Medical Officer)Christina(General Counsel & Chief Operating Officer)
Co-investorsNew Enterprise Associates (NEA)Norwest Venture Partners
A US-based biotechnology company developing ultra-long-acting medicines for obesity and metabolic diseases using half-life extension technology.
Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals.
BiotechDeep Tech
Gary Ashley(Co-Founder)Daniel Santi(Co-Founder)inChris Boulton(CEO)inSimon Harnest(Chief Financial Officer)inAmer Mirza(Chief Scientific Officer)inChristian Weyer(Chief Medical Officer)in
Co-investorsOrbiMed
A clinical-stage neuro-immunology company advancing TYK2 inhibitors for multiple sclerosis and psoriasis.
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)Scott Byrd(Executive Officer, Director)
Co-investorsFrazier Life SciencesSanofi VenturesSV Health InvestorsDementia Discovery FundTPG
UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology.
BiotechHealthtechMedical DevicesPrinceton, US
Elizabeth Barrett(Executive Officer, Director)Mark Schoenberg, M.D.(Executive Officer)Liz Barrett(President and Chief Executive Officer)Jason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)
Co-investorsAisling CapitalPontifax Venture Capital
Exits · 1
IPOs and acquisitions across the tracked portfolioHI-Bioacq. by Biogen
Portfolio news
latest coverage across their companiesUrogen · investing.com · Aug 19, 2026
Ollin Biosciences, Inc. · finsmes.com · Jun 24, 2026
Nocion Therapeutics · nociontx.com · Mar 20, 2026
Frequently asked questions
- How many investments has Monograph Capital Partners made?
- Monograph Capital Partners has 23 tracked investments, 2 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
- What stage does Monograph Capital Partners invest at?
- Monograph Capital Partners invests at the Seed, Series A, Series B stages.
- What sectors does Monograph Capital Partners focus on?
- Monograph Capital Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is Monograph Capital Partners located?
- Monograph Capital Partners is headquartered in London, GB.
- Does Monograph Capital Partners lead rounds?
- Yes, Monograph Capital Partners leads investment rounds.
- Who does Monograph Capital Partners co-invest with?
- Monograph Capital Partners most often shares deals with LifeArc Ventures, New Enterprise Associates (NEA), ARCH Venture Partners, among 42 tracked co-investors.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.